Cellectis SA (CLLS) has released an update.
Cellectis SA is set to present groundbreaking data on their gene-editing technologies at the ESGCT Annual Congress, showcasing advancements in TALE base editors and non-viral gene insertion methods. These developments could significantly enhance therapeutic applications, offering promising new avenues for gene therapy in hematopoietic stem and progenitor cells. Investors may find these innovations indicative of Cellectis’ potential for influencing future gene therapy markets.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
